HOME > TOP STORIES
TOP STORIES
-
BUSINESS AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
-
BUSINESS Janssen’s Darzquro, Chugai’s Polivy, JCR’s Izcargo Now Available in Japan
May 20, 2021
-
BUSINESS 5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot
May 19, 2021
-
REGULATORY Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
-
REGULATORY AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
-
BUSINESS Big 4 Wholesalers’ Operating Margin Sinks to 0.49% on COVID-19, Competition
May 17, 2021
-
BUSINESS 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
-
REGULATORY Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
-
BUSINESS FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
-
BUSINESS Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
-
REGULATORY Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
-
REGULATORY Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
-
REGULATORY May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
-
REGULATORY Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
-
REGULATORY Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
-
BUSINESS Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
-
BUSINESS Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
-
ORGANIZATION JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
-
BUSINESS Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
-
BUSINESS Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
